The race to develop breakthrough treatments for blindness-related diseases is accelerating. In a major move for the ophthalmology market, Bayer has announced plans to fully acquire Perfuse Therapeutics, a clinical-stage biotech company focused on ischemia-induced ocular diseases.
The acquisition gives Bayer full rights to PER-001, a phase II investigational therapy being developed for glaucoma and diabetic retinopathy (DR). The deal carries a total potential value of up to $2.45 billion, including a $300 million upfront payment and additional milestone-based payouts tied to development, regulatory, and commercial success.
Bayer has been steadily expanding its ophthalmology portfolio, and this acquisition strengthens its position in a therapeutic area with massive unmet medical need.
PER-001 stands out because it targets the underlying ischemic and neurodegenerative components of eye diseases rather than focusing only on symptom management.
According to Bayer, the therapy is being studied for its potential to:
This approach could represent a major shift in how chronic eye diseases are treated.
Juergen Eckhardt, MD, head of business development and licensing at Bayer Pharmaceuticals, emphasized the strategic value of the deal:
“With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.”
PER-001 is an investigational small molecule endothelin receptor antagonist.
Endothelin is known as one of the most potent vasoconstrictors in the human body. Elevated endothelin levels have been associated with several retinal and ocular diseases, including:
The therapy aims to reduce inflammation, vascular dysfunction, and retinal cell death linked to these conditions.
One of the key differentiators of PER-001 is its delivery platform.
The drug is administered through a bio-erodible intravitreal implant using a single-use 25-gauge applicator. The implant is designed to provide sustained drug release over time, potentially reducing treatment burden and improving patient compliance.
This sustained-release strategy has become increasingly important in ophthalmology, where frequent injections remain a major challenge for patients and physicians.
Glaucoma remains the leading cause of irreversible blindness worldwide.
Key statistics highlighted by Bayer include:
This creates a significant opportunity for therapies that can directly protect retinal ganglion cells and preserve vision.
Diabetic retinopathy is another rapidly expanding global health challenge.
Current estimates show:
As diabetes prevalence continues to rise worldwide, demand for effective retinal therapies is expected to grow significantly.
The acquisition aligns closely with Bayer’s broader life sciences strategy and reinforces its commitment to ophthalmology innovation.
For Bayer, the transaction offers several advantages:
The deal also demonstrates continued pharmaceutical industry interest in ophthalmology, particularly in therapies targeting retinal ischemia and neurodegeneration.
Perfuse Therapeutics founder and CEO Sevgi Gurkan, MD, described the acquisition as a natural continuation of the company’s mission.
“Bayer’s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness.”
The acquisition is still subject to regulatory approvals, including antitrust clearance and approval from Perfuse shareholders.
Bayer’s acquisition of Perfuse Therapeutics reflects growing industry confidence in next-generation ophthalmic therapies that go beyond traditional symptom control.
If PER-001 succeeds in clinical development, it could become one of the first therapies designed to address ischemia and neurodegeneration in glaucoma and diabetic retinopathy directly.
For patients facing progressive vision loss, that would represent a meaningful step forward in the fight against blindness.